Characterization of bone only metastasis (BOM) patients (pts) with respect to tumor subtypes (TS).

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 1072-1072
Author(s):  
Amanda Marie Parkes ◽  
Katherine Clifton ◽  
Aydah Al Awadhi ◽  
Oluchi Oke ◽  
Carla L. Warneke ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Diagnosis ◽  
Metastatic Breast ◽  
Breast Cancer Diagnosis ◽  
Cancer Center ◽  
Tumor Subtypes ◽  
Lytic Lesions ◽  
Initial Biopsy ◽  
Md Anderson

1072 Background: Metastatic breast cancer (MBC) pts with BOM are a unique population with limited characterization. Our goal was to characterize the TS of BOM pts, evaluating differences in sites and types of bone metastases (BM), treatment, and survival. Methods: We identified pts followed at MD Anderson Cancer Center from 01/01/1997 to 12/31/2015 for at least 6 months with a BOM diagnosis as first site of metastasis (met). TS was assessed by initial biopsy immunohistochemistry (IHC) (Table 1) with hormone receptor (HR) + defined as ER or PR >10%. Results: We identified 1445 pts with BOM, 1049 with initial biopsy IHC available to group into TS (Table 1). Among BOM pts, the majority had multiple BM at diagnosis (1141/79%), most in both the axial (Ax) and appendicular (App) skeleton (53%). Of the 808 pts with BM categorized on imaging at diagnosis, the majority were lytic (389/48%), with 21% sclerotic, 18% mixed, and 12% blastic. Time from breast cancer diagnosis to first met differed significantly by TS, χ2(3) = 94.33, P< .0001, with median time to met longer for pts with blastic (3.08 years; 95% CI 2.03, 4.24) versus lytic lesions (1.75 years; 95% CI 1.27, 2.17). Conclusions: BOM patients are a unique MBC subpopulation, more commonly found in luminal TS patients. Our study demonstrates prognostic differences in BOM pts specific to TS and emphasizes the need for further study of BOM patients. [Table: see text]

Physical Activity and Survival Subsequent to Metastatic Breast Cancer Diagnosis

2010 ◽  
Author(s):  
Susan Sharp ◽  
Ashleigh Golden ◽  
Cheryl Koopman ◽  
Eric Neri ◽  
David Spiegel
Keyword(s):  
Breast Cancer ◽  
Physical Activity ◽  
Metastatic Breast Cancer ◽  
Cancer Diagnosis ◽  
Metastatic Breast ◽  
Breast Cancer Diagnosis

Long-term neurotoxicity in women with breast cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e23089-e23089
Author(s):  
Fahad Ahmed Faruqi ◽  
Charles L. Loprinzi ◽  
Kathryn Jean Ruddy ◽  
Fergus Couch ◽  
Nathan Staff ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Diagnosis ◽  
Metastatic Breast ◽  
Breast Cancer Diagnosis ◽  
Her2 Positive ◽  
Observation Study ◽  
Initial Exposure ◽  
Sensory Score ◽  
Patient Reported

e23089 Background: Taxanes (paclitaxel and docetaxel) are commonly administered as part of chemotherapy for breast cancer, but long-term data on chemotherapy-induced peripheral neuropathy (CIPN) are limited in this population. We aimed to assess CIPN approximately three years after an initial exposure to paclitaxel or docetaxel. Methods: In a cross-sectional observation study, which surveyed consented enrollees annually after receipt of care at Mayo Clinic for a new breast cancer diagnosis over age 18, we collected patient-reported EORTC CIPN20 data by mailed questionnaire at baseline and three years after a breast cancer diagnosis. We then confirmed patient-reported chemotherapy data by chart abstraction and only included those who had received a standard course of docetaxel-based or paclitaxel-based chemotherapy, but had not had other neurotoxic treatment for cancer. CIPN20 overall and sensory scale raw scores were converted to a 0-100 linear scale with lower scores indicating more severe symptoms. Results: 84 women who received a taxane for breast cancer completed the survey. 82 were treated in the adjuvant or neo-adjuvant setting, while 2 received a taxane for metastatic breast cancer. 67 women received paclitaxel, while 17 received docetaxel. The median age at diagnosis was 51.5 years (range 31-86). 37 had estrogen receptor (ER) and/or progesterone receptor (PR) positive and human epidermal growth factor receptor-2 (Her2) negative, 31 Her2 positive, and 16 triple negative breast cancer. The median CIPN20 score was 92.98 (range 33.33-100). The median sensory CIPN score was 92.59 (range 25.94-100). 81% of women had an overall CIPN20 score of less than 100, and 68% had a sensory score of less than 100. Conclusions: The majority of women who received a taxane based chemotherapy regimen for breast cancer reported at least mild neuropathic symptoms three years out from treatment. Additional research is needed to help tailor chemotherapy decisions to toxicity risks and to reduce the likelihood of long-term CIPN, which can impair quality of life.

Comparisons of survival time in BRCA-positive patients with metastatic breast cancer using electronic health records (EHRs).

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e13004-e13004
Author(s):  
Yookyung Christy Choi ◽  
Jerzy Edward Tyczynski ◽  
Dongmu Zhang
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Survival Time ◽  
Cancer Diagnosis ◽  
Systemic Chemotherapy ◽  
Metastatic Breast ◽  
Breast Cancer Diagnosis ◽  
Study Cohort ◽  
Breast Cancer Patients ◽  
Mutation Status

e13004 Background: BRCA is a hereditary genetic mutation associated with a higher risk of breast cancer at younger age. Generally, BRCA gene testing is done in perceived high-risk individuals, and different management approaches might be considered given the high risk of breast cancer. This study examines treatment outcomes among BRCA-positive, metastatic breast cancer patients with consideration of prophylactic management by using US nationwide EHR data. Methods: This was a retrospective cohort study using Optum EHRs. The study cohort includes female adults who underwent their first systemic chemotherapy for metastatic breast cancer between 2013-2018 with a BRCA positive test result prior to the systemic chemotherapy, with ≥ 6 months baseline period from the chemotherapy. Physicians’ notes captured in Natural Language Processing (NLP) were further used to construct the cohort. Patients were followed from the earliest breast cancer diagnosis date until a censoring event (death or end of observation period). Death information was provided with national death certificate data. Descriptive statistics were used for patient characteristics and a stepwise Cox Proportional Hazard (CPH) regression model was fit to compare survival time. Results: Of 3624 patients included in the cohort, median age at the earliest breast cancer diagnosis is 50 years old (IQR 43-59), and a total of 540 (14.9%) deaths was observed. Prior to systemic chemotherapy, 1430 (39.5%) received mastectomy/lumpsectomy. 571 (15.8%) received hormone therapy prior to systemic chemotherapy. 646 (17.8%) had a clinical record indicating a triple negative breast cancer (TNBC). 2196 (60.6%) received more than 1 line of chemotherapy. Overall median survival days in the study cohort was 3778 days from the earliest breast cancer diagnosis. Median survival days in those with ER/PR positive and with TNBC status were 4150 days and 3124 days, respectively. From the CPH model, age, tumor mutation status, and prior mastectomy/lumpectomy were identified as significant factors; Hazard Ratio (HR) with each 1 year older in age at diagnosis was 1.02 (95% CL 1.01-1.03), that of TNBC vs ER/PR positive status was 2.27 (95% CL 1.87-2.77) and that of those with prior surgery vs without was 0.567 (95% CL 0.457-0.703). Conclusions: This study demonstrated the utility of EHR database for survival analysis. In metastatic breast cancer patients with a known BRCA-positive status, age at the initial diagnosis, tumor mutation status, and prior mastectomy/lumpectomy were significant factors in survival time.

Effects of an outreach and internal navigation program on breast cancer diagnosis in an urban cancer center with a large African-American population

Cancer ◽  
2008 ◽  
Vol 113 (3) ◽  
pp. 602-607 ◽  
Author(s):  
Sheryl G. A. Gabram ◽  
Mary Jo B. Lund ◽  
Jessica Gardner ◽  
Nadjo Hatchett ◽  
Harvey L. Bumpers ◽  
...  
Keyword(s):  
Breast Cancer ◽  
African American ◽  
Cancer Diagnosis ◽  
Breast Cancer Diagnosis ◽  
Cancer Center ◽  
American Population ◽  
African American Population ◽  
Navigation Program

scholarly journals Invasive breast tumors are characterized by the presence of crystalline nanoparticles

2020 ◽  
Author(s):  
Elena Tsolaki ◽  
William Doran ◽  
Luca Magnani ◽  
Alessandro Olivo ◽  
Inge K. Herrmann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Diagnosis ◽  
Breast Tissue ◽  
Arterial Wall ◽  
Breast Cancer Diagnosis ◽  
Malignant Tumour ◽  
Spherical Particles ◽  
Tumour Tissue ◽  
Tissue Samples

The presence of calcification in tumours has been known for decades1. Indeed, calcified breast tissue is a fundamental criterion for early breast cancer diagnosis, indicative of malignancies2, and their appearance is used to distinguish between benign and malignant in breast biopsies3,4. However, an in-depth characterization of the nature and origin of tumour tissue calcification remains elusive5–8. Here, we report the presence of nano and micron-sized spherical particles made of highly crystalline whitlockite that are exclusively found in the arterial wall of malignant invasive tumours. By applying nanoanalytical methods to healthy, benign and malignant tumour breast tissue biopsies from patients, we show that poorly crystalline apatite can be found in all breast tissue samples, whereas spherical crystalline whitlockite particles are present only in invasive cancers, mainly in areas close to the lumen of the arterial wall. Moreover, we demonstrate that the concentration of these spherical crystalline particles increases with the grade of disease, and that their size can be related to tumour type. Therefore, our results not only provide new insight into calcification of tumour tissue, but also enable a precise, yet simple route of breast cancer diagnosis and staging.

Sign in / Sign up

Export Citation Format

Share Document